Delivery Order SPE2DB20D1051-SPE2DB25FD8AK

Award Date 5/7/25
Potential Completion Date 5/8/25
Potential Value $13K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $15,170.10 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL, a medication used to treat diabetes. The award has an ultimate completion date of June 11, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The contract has a ceiling value of $6,051.67 and a performance period through April 23, 2025. This order is not set aside and represents open competition. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,465.59, is for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a medication used to manage diabetes. The award has an ultimate completion date of April 9, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml medication. The award, valued at $15,871.71, has a completion date of January 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This is a $15,737.88 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the purchase of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a diabetes medication. The award has an ultimate completion date of January 23, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,718.72 contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The award has an ultimate completion date of April 16, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This is a $1,415.94 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication, to support military healthcare programs. The award is not designated as a set-aside contract. The contract has an ultimate completion date of July 19, 2024. AmerisourceBergen holds a $999,999,999 indefinite delivery contract (IDC) with the...
This is a Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,015.94, is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The contract has an ultimate completion date of October 16, 2023. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL, a diabetes medication. The award has a ceiling value of $2,819.97 and a period of performance through April 30, 2025. The contract is not set-aside and was competed openly. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $3,160.91 contract is for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a diabetes medication, with a period of performance through March 27, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
  • SPE2DB20D1051
    Indefinite Delivery Contract
  • SPE2DB20D1051-SPE2DB25FD8AK
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $13,187.10 contract provides the DLA with Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The award has a May 2025 completion date and is not a set-aside. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle through December 2026, enabling the company to supply a wide range of medications and medical supplies to military and other government healthcare programs.

Generated 8/6/25, 9:42 AM